{{Rsnum
|rsid=6139030
|Gene=ITPA
|Chromosome=20
|position=3207087
|Orientation=plus
|GMAF=0.09826
|Gene_s=ITPA
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}Carriers of the C allele at [[rs6139030]] have a higher risk of developing [[thrombocytopenia]] when treated with [[interferon]]. {{PMID|21659334}}

{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 14.3 | 85.7
| HCB | 2.9 | 17.5 | 79.6
| JPT | 0.9 | 26.5 | 72.6
| YRI | 0.7 | 21.1 | 78.2
| ASW | 0.0 | 12.3 | 87.7
| CHB | 2.9 | 17.5 | 79.6
| CHD | 3.7 | 27.5 | 68.8
| GIH | 1.0 | 24.8 | 74.3
| LWK | 0.9 | 23.9 | 75.2
| MEX | 1.7 | 6.9 | 91.4
| MKK | 0.6 | 8.3 | 91.0
| TSI | 0.0 | 20.6 | 79.4
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=21659334
|Trait=None
|Title=Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
|RiskAllele=C
|Pval=1E-15
|OR=3.9000
|ORtxt=[2.80-5.50]
}}

[[Hepatitis C Treatment Side Effects]]

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}